Compare DPRO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | CRBP |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 170.3M |
| IPO Year | N/A | N/A |
| Metric | DPRO | CRBP |
|---|---|---|
| Price | $7.19 | $8.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $15.67 | ★ $50.29 |
| AVG Volume (30 Days) | ★ 1.5M | 493.9K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,335,758.00 | N/A |
| Revenue This Year | $50.81 | N/A |
| Revenue Next Year | $149.77 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.74 | N/A |
| 52 Week Low | $1.63 | $4.64 |
| 52 Week High | $14.40 | $20.56 |
| Indicator | DPRO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 30.34 |
| Support Level | $6.56 | $7.97 |
| Resistance Level | $8.36 | $8.54 |
| Average True Range (ATR) | 0.64 | 0.46 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 47.85 | 6.47 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.